The Effect of on Macrophage Polarization and T Cell Immunity by Targeting in Breast Cancer

Overview

Journal J Oncol

Specialty Oncology

Date 2021 Oct 18

PMID 34659411

Citations 6

Authors

Qin Zhu

Jiaqi Yuan

Yuqiong He

Yu Hu

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer is the most common cancer in women. had binding sites with through the bioinformatics prediction. But few studies have been conducted on and in breast cancer. We aimed to explore the effect of and on breast cancer and the mechanisms involved.

Methods: Clinical samples of breast cancer were collected. Bioinformatics analysis was performed to screen the differentially expressed miRNAs. CD4 T cells and CD8 T cells were cocultured with MCF-7 cells in the Transwell system. Moreover, MCF-7 cells and M0 macrophage cocultured cell lines were constructed. qRT-PCR, IF, western blot, flow cytometry, and ELISA were performed to detect related factors expression. Starbase and dual-luciferase reporter assay verified the binding of to . The tumor formation model was established to study and effects .

Results: The differentially expressed was screened via miRNAs sequencing and cell verification. expression was high, was low in tumor tissues, T cells and NK cells were inhibited, and macrophages were transformed into M2 type, promoting immune escape. In addition, bound to . Then, splenic CD4 T cells and CD8 T cells were successfully sorted. During CD4 T cell differentiation to Th1 and Treg, Th1 was inhibited, and Treg was activated. We found the polarization of macrophages was related to breast cancer. The proportion of CD206 cells increased and CD68 cells decreased in the mimics group compared with the mimic NC group. Compared with the inhibitor NC group, the proportion of CD206 cells decreased, and CD68 cells increased in the inhibitor group. experiments showed that inhibitor inhibited tumor growth and promoted expression. The proportion of CD3, CD4, CD8, NK1.1, CD4+IFN, and CD68 cells increased, while FOXP3 and CD206 cells decreased in the inhibitor group compared with the inhibitor NC group. However, the proportion of CD3, CD4, CD8, NK1.1, CD4+IFN, and CD68 cells decreased, while FOXP3 and CD206 cells increased after the addition of si.

Conclusions: inhibited and aggravated breast tumors. inhibitor enhanced CD4 and CD8 cell populations in the tumor immune microenvironment and inhibited tumor growth.

Citing Articles

Treg Cell Therapeutic Strategies for Breast Cancer: Holistic to Local Aspects.

Zhang H, Felthaus O, Eigenberger A, Klein S, Prantl L Cells. 2024; 13(18.

PMID: 39329710 PMC: 11429654. DOI: 10.3390/cells13181526.

Inflammatory Changes after Medical Suppression of Suspected Endometriosis for Implantation Failure: Preliminary Results.

Lessey B, Dong A, Deaton J, Angress D, Savaris R, Walker S Int J Mol Sci. 2024; 25(13).

PMID: 38999962 PMC: 11241468. DOI: 10.3390/ijms25136852.

Non-coding RNA in tumor-infiltrating regulatory T cells formation and associated immunotherapy.

Ma Y, Xu X, Wang H, Liu Y, Piao H Front Immunol. 2023; 14:1228331.

PMID: 37671150 PMC: 10475737. DOI: 10.3389/fimmu.2023.1228331.

Breast cancer tumor microenvironment affects Treg/IL-17-producing Treg/Th17 cell axis: Molecular and therapeutic perspectives.

Seif F, Torki Z, Zalpoor H, Habibi M, Pornour M Mol Ther Oncolytics. 2023; 28:132-157.

PMID: 36816749 PMC: 9922830. DOI: 10.1016/j.omto.2023.01.001.

Exosome-transmitted S100A4 induces immunosuppression and non-small cell lung cancer development by activating STAT3.

Wu X, Zhang H, Jiang G, Peng M, Li C, Lu J Clin Exp Immunol. 2022; 210(3):309-320.

PMID: 36370151 PMC: 9985167. DOI: 10.1093/cei/uxac102.

References

Kulkoyluoglu-Cotul E, Arca A, Madak-Erdogan Z . Crosstalk between Estrogen Signaling and Breast Cancer Metabolism. Trends Endocrinol Metab. 2018; 30(1):25-38. DOI: 10.1016/j.tem.2018.10.006. View

Zhang H, Lang T, Zou D, Zhou L, Lou M, Liu J . miR-520b Promotes Breast Cancer Stemness Through Hippo/YAP Signaling Pathway. Onco Targets Ther. 2020; 12:11691-11700. PMC: 6942529. DOI: 10.2147/OTT.S236607. View

Cimino-Mathews A, Foote J, Emens L . Immune targeting in breast cancer. Oncology (Williston Park). 2015; 29(5):375-85. View

Jarosz-Biej M, Smolarczyk R, Cichon T, Kulach N . Tumor Microenvironment as A "Game Changer" in Cancer Radiotherapy. Int J Mol Sci. 2019; 20(13). PMC: 6650939. DOI: 10.3390/ijms20133212. View

Ullah M . Breast Cancer: Current Perspectives on the Disease Status. Adv Exp Med Biol. 2019; 1152:51-64. DOI: 10.1007/978-3-030-20301-6_4. View

Faghih Z, Erfani N, Haghshenas M, Safaei A, Talei A, Ghaderi A . Immune profiles of CD4+ lymphocyte subsets in breast cancer tumor draining lymph nodes. Immunol Lett. 2013; 158(1-2):57-65. DOI: 10.1016/j.imlet.2013.11.021. View

Hawse W, Sheehan R, Miskov-Zivanov N, Menk A, Kane L, Faeder J . Cutting Edge: Differential Regulation of PTEN by TCR, Akt, and FoxO1 Controls CD4+ T Cell Fate Decisions. J Immunol. 2015; 194(10):4615-9. PMC: 4418530. DOI: 10.4049/jimmunol.1402554. View

Kishimoto H, Ohteki T, Yajima N, Kawahara K, Natsui M, Kawarasaki S . The Pten/PI3K pathway governs the homeostasis of Valpha14iNKT cells. Blood. 2006; 109(8):3316-24. DOI: 10.1182/blood-2006-07-038059. View

Sabit H, Cevik E, Tombuloglu H, Abdel-Ghany S, Tombuloglu G, Esteller M . Triple negative breast cancer in the era of miRNA. Crit Rev Oncol Hematol. 2020; 157:103196. DOI: 10.1016/j.critrevonc.2020.103196. View

10.

Yang J, Yan J, Shao J, Xu Q, Meng F, Chen F . Immune-Mediated Antitumor Effect By VEGFR2 Selective Inhibitor For Gastric Cancer. Onco Targets Ther. 2019; 12:9757-9765. PMC: 6863181. DOI: 10.2147/OTT.S233496. View

11.

Huang Y, Ma C, Zhang Q, Ye J, Wang F, Zhang Y . CD4+ and CD8+ T cells have opposing roles in breast cancer progression and outcome. Oncotarget. 2015; 6(19):17462-78. PMC: 4627321. DOI: 10.18632/oncotarget.3958. View

12.

Saha T, Makar S, Swetha R, Gutti G, Singh S . Estrogen signaling: An emanating therapeutic target for breast cancer treatment. Eur J Med Chem. 2019; 177:116-143. DOI: 10.1016/j.ejmech.2019.05.023. View

13.

Grzes K, Swamy M, Hukelmann J, Emslie E, Sinclair L, Cantrell D . Control of amino acid transport coordinates metabolic reprogramming in T-cell malignancy. Leukemia. 2017; 31(12):2771-2779. PMC: 5729345. DOI: 10.1038/leu.2017.160. View

14.

Orecchioni M, Ghosheh Y, Pramod A, Ley K . Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS-) vs. Alternatively Activated Macrophages. Front Immunol. 2019; 10:1084. PMC: 6543837. DOI: 10.3389/fimmu.2019.01084. View

15.

Li D, Ji H, Niu X, Yin L, Wang Y, Gu Y . Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer. Cancer Sci. 2019; 111(1):47-58. PMC: 6942430. DOI: 10.1111/cas.14230. View

16.

Rask L, Balslev E, Sokilde R, Hogdall E, Flyger H, Eriksen J . Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status. Cell Oncol (Dordr). 2014; 37(3):215-27. DOI: 10.1007/s13402-014-0176-6. View

17.

Mehraj U, Dar A, Wani N, Mir M . Tumor microenvironment promotes breast cancer chemoresistance. Cancer Chemother Pharmacol. 2021; 87(2):147-158. DOI: 10.1007/s00280-020-04222-w. View

18.

Yeo S, Guan J . Breast Cancer: Multiple Subtypes within a Tumor?. Trends Cancer. 2017; 3(11):753-760. PMC: 5802368. DOI: 10.1016/j.trecan.2017.09.001. View

19.

Hu N, Zhang J, Cui W, Kong G, Zhang S, Yue L . miR-520b regulates migration of breast cancer cells by targeting hepatitis B X-interacting protein and interleukin-8. J Biol Chem. 2011; 286(15):13714-22. PMC: 3075715. DOI: 10.1074/jbc.M110.204131. View

20.

Zander R, Schauder D, Xin G, Nguyen C, Wu X, Zajac A . CD4 T Cell Help Is Required for the Formation of a Cytolytic CD8 T Cell Subset that Protects against Chronic Infection and Cancer. Immunity. 2019; 51(6):1028-1042.e4. PMC: 6929322. DOI: 10.1016/j.immuni.2019.10.009. View